Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

Lancet Infectious Diseases
Jul 2020 Volume 20 Number 7 p755-874, e148-e179
http://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
Pedro M Folegatti, et al